ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Lisata Therapeutics Inc

Lisata Therapeutics Inc (LSTA)

3.65
-0.03
(-0.82%)
Closed July 15 4:00PM
3.65
0.00
( 0.00% )
Pre Market: 4:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.65
Bid
3.62
Ask
3.70
Volume
-
0.00 Day's Range 0.00
1.95 52 Week Range 3.8699
Market Cap
Previous Close
3.65
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
16,394
Shares Outstanding
8,307,433
Dividend Yield
-
PE Ratio
-1.45
Earnings Per Share (EPS)
-2.51
Revenue
-
Net Profit
-20.84M

About Lisata Therapeutics Inc

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Sector
Health & Allied Services,nec
Industry
Insurance Carriers, Nec
Headquarters
Wilmington, Delaware, USA
Founded
2006
Lisata Therapeutics Inc is listed in the Health & Allied Services sector of the NASDAQ with ticker LSTA. The last closing price for Lisata Therapeutics was $3.65. Over the last year, Lisata Therapeutics shares have traded in a share price range of $ 1.95 to $ 3.8699.

Lisata Therapeutics currently has 8,307,433 shares outstanding. The market capitalization of Lisata Therapeutics is $30.32 million. Lisata Therapeutics has a price to earnings ratio (PE ratio) of -1.45.

LSTA Latest News

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024...

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024...

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference...

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.38.95522388063.353.753.3171135533.55374312CS
40.25.797101449283.453.753.22175343.46440253CS
120.9937.21804511282.663.752.51163943.27620413CS
260.5818.89250814333.073.752.42144113.1753107CS
52-0.05-1.351351351353.73.86991.95198362.80314883CS
156-5.15-58.52272727278.89.381.95234623.85183389CS
260-5.15-58.52272727278.89.381.95234623.85183389CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CDTConduit Pharmaceuticals Inc
$ 0.4342
(80.92%)
21.05M
WNWMeiwu Technology Company Ltd
$ 1.32
(48.31%)
2.66M
SYRASyra Health Corporation
$ 1.75
(31.09%)
1
WINTWindtree Therapeutics Inc
$ 4.50
(21.62%)
10
CMNDClearmind Medicine Inc
$ 2.61
(17.57%)
34.64k
GRNQGreenpro Capital Corporation
$ 0.9376
(-20.54%)
92.61k
AMIXAutonomix Medical Inc
$ 1.13
(-18.12%)
450.78k
LXEHLixiang Education Holding Company Ltd
$ 0.2994
(-15.73%)
460.71k
TANHTantech Holdings Ltd
$ 0.518
(-15.23%)
1.15M
AREBAmerican Rebel Holdings Inc
$ 0.571
(-15.16%)
153.28k
CDTConduit Pharmaceuticals Inc
$ 0.4369
(82.04%)
21.01M
KRKR36Kr Holdings Inc
$ 0.3187
(7.23%)
4.78M
WNWMeiwu Technology Company Ltd
$ 1.38
(55.06%)
2.59M
SLNASelina Hospitality PLC
$ 0.0662
(5.75%)
2.5M
MAXNMaxeon Solar Technologies Ltd
$ 0.22
(-3.08%)
1.52M

LSTA Discussion

View Posts
TheFinalCD TheFinalCD 2 years ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169956690
👍️0
subslover subslover 2 years ago
Never mind I see they did change the ticker and wow great job. CUDOS to you!
👍️0
tedgoeseast tedgoeseast 2 years ago
The ticker it is LSTA get on etrade market castor that is what I am on
👍️0
subslover subslover 2 years ago
Did they change the ticker?tia
👍️0
tedgoeseast tedgoeseast 2 years ago
It going through the roof right now I left 5000 on the table who knew it was going over 9.00 wow volume at over 627000 now premarket
👍️0
TheFinalCD TheFinalCD 2 years ago
CONGRAT$
👍️0
tedgoeseast tedgoeseast 2 years ago
It shows 615000 premarket on etrade market castor and it over 9.00 a share now wow
👍️0
subslover subslover 2 years ago
But the stock shows 0 trades pre mkt???
👍️0
tedgoeseast tedgoeseast 2 years ago
Clbs my second best play this week wow!! When everyone was saying it was tanking big time sold this morning for a nice Gain
👍️0
tedgoeseast tedgoeseast 2 years ago
Wow I got up this morning and it was over 7.50 I called etrade and they put my sell order through I just made 2400.00 profit when everyone even moonmarket said it was a bad trade for him ,I bought at .40 yesterday 7.50is like selling it for .60 at the old share structure
👍️0
subslover subslover 2 years ago
You're absolutely correct. I will keep this on watch.
👍️0
TheFinalCD TheFinalCD 2 years ago
lately everything is a pnd, they push it up too high and short it back

with some exceptions, that have a few day run
👍️0
tedgoeseast tedgoeseast 2 years ago
I have been reading all about it on OTC site and stock twits I put a bid in for .385 just for the fun of it
👍️0
PStockPickz PStockPickz 2 years ago
Merger news this morning mixed with the r/s is why I bought. Took loss and keeping it on radar for reversal
👍️0
tedgoeseast tedgoeseast 2 years ago
YOU BOUGHT AT .63 IT WAS JUST AT .385
👍️0
subslover subslover 2 years ago
Yea, nothing surprises me
👍️0
PStockPickz PStockPickz 2 years ago
Looks like a group wacked out to chase another ticker
👍️0
krisc62 krisc62 2 years ago
Watching for bounce from 52 WL
👍️0
subslover subslover 2 years ago
I didn't get the memo. lol
👍️0
PStockPickz PStockPickz 2 years ago
Maybe someone didn't get the memo that r/s plays are hot right now haha
👍️0
PStockPickz PStockPickz 2 years ago
Snagged 63s
👍️0
subslover subslover 2 years ago
LMAO!
👍️0
TheFinalCD TheFinalCD 2 years ago
LOLme2
👍️0
subslover subslover 2 years ago
This is a very unusual year with all the R/S working out! Scratching my bald head!
👍️0
TheFinalCD TheFinalCD 2 years ago
post RS plays are HOT **CLBS* +Merger

adtx nrbo
👍️0
PStockPickz PStockPickz 2 years ago
Yep double whammy r/s and merger. Surprised this isn't getting more attention
👍️0
subslover subslover 2 years ago
Merger in progress
👍️0
PStockPickz PStockPickz 2 years ago
R/s after the close. Could be another big runner
👍️0
conix conix 3 years ago
Dawson James - Caladrius (CLBS) - Delays, Delays & delays + Burning Cash

Caladrius has fallen to $0.90 from $1.61 (2.15.21) when we wrote "Dam the Shareholders Full Speed Ahead", commenting on the highly dilutive capital raise. Revisiting the story, we see little progress. Caladrius reported 3Q21 results spending $7M in the quarter, steadily whittling down its $100M in cash balance but to what end? We note multiple delays across previously promoted programs such as CLI in Japan, now suspended.
Click here for the full report


HONDERA (CLBS12) – Suspended for CLI in Japan –This was planned as a small Phase 2 study, an interventional, open-label, proof-of-concept (POC) trial planned for two centers, but the company had problems finding patients, blaming COVID. Caladrius now says the program is suspended until a Japanese partner is identified. We remain skeptical and see this program as "dead."

XOWNA (CLBS16) – Enrollment has Slowed: The product is currently being evaluated in a P2b study in patients with CMD and without obstructive coronary artery disease. Patient enrollment is behind schedule, so the company has been expanding the number of sites and modifying the study protocol. These protocol amendments were implemented in the latter part of the quarter. We see these as "red flags."

Management was Pushing the CD34+ cells as a COVID Play – This appears to have fizzled out. Is anyone surprised? What's the Problem? On just about every level, we find management's explanations across multiple programs as lacking. Management seems to lack an understanding of 1. the competitive environment. Multiple off-the-shelf, allogeneic companies are already treating COVID patients but on ventilators and potentially earlier, and recent failures of other cell therapies in COVID due to improved standard of care. 2. For example, in COVID, using cells to ameliorate the after-effects of ventilator therapy for COVID patients is a great idea, BUT a) harvesting cells from these patients is not ideal; b) how do you measure how effective your treatment is? For NORDA, we see a POC trial as a $65M and multi-year investment. What size trial is needed to measure the effect versus standard of care? 3. Caladrius's autologous therapy is very late in the field.

Valuation. For Caladrius, we previously lowered our rating to Neutral from Buy (March 2020) and removed our price target. Our model uses our highest discount rate of 30% in our free cash flow to the Firm (FCFF), discounted EPS, and Sum of the Parts (SOP) models. Our models go out to 2029 and have been updated for the recent dilution. The company now has a negative enterprise value, but we believe that won't last as its likely management will now be on a spending spree. Spending on clinical trials that we feel go nowhere and or looking to make an acquisition. Our bottom-line concern is that Caladrius has, in our opinion, missed the window. Allogenic competitors are advancing now in heart failure, back pain, stroke, CLI, GvHD, and three companies are today treating COVID patients for ARDS

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

👍️0
Roadtojourney Roadtojourney 3 years ago
Got new bagholders pos imo
👍️0
slow_feet slow_feet 3 years ago
SI as of 2/12/21


2/12/2021 1,450,000 shares
1/29/2021 2,930,000 shares
1/15/2021 127,600 shares
12/31/2020 130,000 shares
12/15/2020 130,000 shares
👍️0
slow_feet slow_feet 3 years ago
Four funds have new positions as of 2/12/21: https://whalewisdom.com/stock/nbs-2

👍️0
CINCY_4MONEY CINCY_4MONEY 3 years ago
this stock is hot. they have a 9 a share 1st year target we will get there soon
👍️0
slow_feet slow_feet 3 years ago
Opened a cr*p-load of April Calls in the AM.

C'mon 7!
👍️0
ClayTrader ClayTrader 3 years ago
* * $CLBS Video Chart 01-20-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
hotonthemoney hotonthemoney 3 years ago
Why Caladrius Biosciences Is Soaring Today
Why Caladrius Biosciences Is Soaring Today
👍️0
hotonthemoney hotonthemoney 3 years ago
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
👍️0
Carioca Carioca 3 years ago
weregoingherecscw
👍️0
Ruffieruff Ruffieruff 3 years ago
Out as well. Pulled a profit so all good. Gltu
👍️0
wickerman wickerman 3 years ago
$CLBS out core $4.05 will revisit..patience + DD forever

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

https://www.biospace.com/article/releases/caladrius-biosciences-treats-first-patient-in-the-phase-2b-freedom-trial-of-clbs16-for-the-treatment-of-coronary-microvascular-dysfunction/#:~:text=(Nasdaq%3A%20CLBS)%20(%E2%80%9C,dysfunction%20(%E2%80%9CCMD%E2%80%9D)%20at
👍️0
Docstemcell2020 Docstemcell2020 3 years ago
Nice
👍️0
AlphaStockNews AlphaStockNews 3 years ago
$CLBS is squeezing the shorts out of their positions following an announcement of a patient treated in a Phase 2b trial. https://cnafinance.com/clbs-stock-caladrius-biosciences-squeezes-shorts/
👍️0
Ruffieruff Ruffieruff 3 years ago
14PT this morning. Huge move ahead.
👍️0
Ruffieruff Ruffieruff 4 years ago
Figured you were long out. Now this bomb confirms it.
👍️0
Ruffieruff Ruffieruff 4 years ago
Have you sold and moved on. Very quiet around here.
👍️0
Ruffieruff Ruffieruff 4 years ago
Falling apart here. Are we do any updates anytime soon?
👍️0
Ruffieruff Ruffieruff 4 years ago
How much patience does one need. We are going sideways and it’s not too much fun.
👍️0
Swimmingly Swimmingly 4 years ago
Bought a few more cheapies today. Just have to be patient with this one.
👍️0
Ruffieruff Ruffieruff 4 years ago
Unfortunately not looking so hot for us who bought in much higher.
👍️0
Swimmingly Swimmingly 4 years ago
They sure are. GL
👍️0

Your Recent History

Delayed Upgrade Clock